ADCT

ADC Therapeutics SA

1.35 USD

Last updated Sep 4, 21:06 UTC

Yesterday HIGH

$1.37

Yesterday LOW

$1.3

52w HIGH

$4.97

52w LOW

$0.78

EPS

-0.11

PE

-12.27

Next Earnings

Nov 9, 2026

Overview News Government Trades Fundamentals

ADC Therapeutics SA stock is up 26.17% since 30 days ago. The next earnings date is Nov 9, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 6 September’s closed higher than August. 100% of analysts rate it a buy.

Avi Kapoor

Thu Jun 4, 2026

Why PVH Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket

Shares of PVH fell 21.42% in pre-market trading even after strong Q1. Gainers include CXApp, TaoWeave. Losers include Hub Cyber Security.
Benzinga Insights

Wed Jun 3, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Newsdesk

Wed Jun 3, 2026

ADC Therapeutics shares are trading lower after the company announced topline data from its Phase 3 LOTIS-5 confiramtory trial evaluating ZYLNLONTA in combination with rituximab. The company indicated that LOTIS-5 showed elevated serious and Grade 5 adverse events and it will discuss the benefit-risk profile with the FDA.
Benzinga Newsdesk

Wed Jun 3, 2026

ADC Therapeutics LOTIS-5 Shows Elevated Serious And Grade 5 Adverse Events; Faces FDA Benefit–Risk Scrutiny
Benzinga Newsdesk

Wed Jun 3, 2026

ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA In Combination With Rituximab In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial
Benzinga Newsdesk

Tue May 5, 2026

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.
Benzinga Newsdesk

Tue May 5, 2026

HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.
Benzinga Insights

Mon May 4, 2026

Full Transcript: ADC Therapeutics Q1 2026 Earnings Call
Benzinga Newsdesk

Mon May 4, 2026

ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the
Benzinga Insights

Mon May 4, 2026

Earnings Scheduled For May 4, 2026

Guggenheim

Mon Aug 17, 15:32

buy

confirm

Advanced Data Unlock

DIA $532.33 USD

NVTS $11.81 USD

MSTX MSTX $16.80 USD

LULU $100.57 USD

SNDK $1,730.23 USD

SKHY SKHY $176.99 USD

NFLX $78.29 USD

PSKY $10.87 USD

NTLA $12.75 USD